Alder Biopharmaceuticals Inc (ALDR.OQ)
Tue, Nov 7 2017
* Alder biopharmaceuticals announces third quarter 2017 financial and operating results
* Alder Biopharmaceuticals announces second quarter 2017 financial and operating results
* Alder Biopharmaceuticals, Inc. announces commencement of public offering of common stock
Alder BioPharmaceuticals Inc's late-stage study data on its experimental treatment to prevent episodic migraine fell short of investor expectations, sending its shares plunging as much as 26 percent to a more than two-and-half year low.
* Shares fall as much as 26 pct to 2 1/2 yr-low (Adds analyst comment, updates shares)
* Alder Biopharmaceuticals announces positive eptinezumab phase 3 results for prevention of frequent episodic migraine
June 27 Alder BioPharmaceuticals Inc said on Tuesday its experimental treatment to prevent episodic migraine met the main goal of reducing monthly migraine days in a late-stage study.
- Alder's (ALDR) CEO Randy Schatzman on Q3 2017 Results - Earnings Call Transcript
- Your Daily Pharma Scoop: Celgene's Big Fall, Tesaro VARUBI Approval, TGTX Midstage Success
- Your Daily Pharma Scoop: Gilead's Brave New World, AZN's Lynparza SNDA, RXDX Entrectinib Shows Positive Results
- Week 42 Breakout Forecast: Short-Term Picks To Give You An Edge
- Week 41 Breakout Forecast: Short-Term Picks To Give You An Edge
- Week 40 Breakout Forecast: Short-Term Picks To Give You An Edge